• A K Nowak, N R C Wilcken, M R Stockler, A Hamilton, and D Ghersi.
• National Health and Medical Research Centre Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia. annan@ctc.usyd.edu.au
• Lancet Oncol. 2004 Jun 1; 5 (6): 372-80.

AbstractThe use of taxanes in early breast cancer is increasing. However, there are few mature studies of taxanes in this setting, and their role is uncertain. Our systematic review of randomised trials of adjuvant or neoadjuvant systemic therapy identified ten reported trials comparing a taxane-containing group with a non-taxane-containing control group in women with early breast cancer. Four of five neoadjuvant trials showed higher rates of complete response with taxanes, although differences were not significant. All five adjuvant trials showed improvements in disease-free survival with taxanes, and these improvements were significant in three trials and independent of oestrogen-receptor status. Two trials showed a significant improvement in overall survival. These results support the use of adjuvant taxanes in women with early breast cancer and involved lymph nodes. Longer follow-up of these trials and results from continuing trials are needed to clarify the best use of taxanes in early breast cancer.

30 keywords...

hide…